Leighandra Barber, APRN
Family · Lexington, KYNPI 1376921916
Payments from drug & device makers
Across 284 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$749
- CSL Behring$268
- Amgen$262
- Pfizer$236
- plus $1K from 20 others
What the payments were for
- Consulting fees$270%
- Food & beverage$5,66195%
- Education$2544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 79 | $1,887 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,179 |
| GSK | 55 | $749 |
| CSL Behring | 10 | $268 |
| Amgen | 13 | $262 |
| Pfizer | 13 | $236 |
| AstraZeneca | 11 | $195 |
| Genentech USA, Inc. | 11 | $191 |
| Sanofi-aventis U.S. LLC | 2 | $147 |
| LEO Pharma Inc. | 5 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $133 |
| Octapharma USA, Inc. | 3 | $69 |
| Kaleo, Inc. | 4 | $62 |
| Blueprint Medicines Corporation | 3 | $61 |
| Novartis | 2 | $52 |
| Covis Pharma GmbH | 3 | $48 |
| Incyte Corporation | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $37 |
| ADMA Biomanufacturing LLC | 1 | $27 |
| Pharming Healthcare, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $25 |
| Invivyd Inc | 1 | $25 |
| Alk-abello, Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $14 |
How this compares
$5,942 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 68 | $254,476 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 208 | $167,834 |
| Dupixent SyringeDupilumab | 23 | $109,725 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $35,703 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $11,548 |
| DuleraMometasone/Formoterol | 29 | $10,702 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,884 |
| Arnuity ElliptaFluticasone Furoate | 28 | $9,413 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,295 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $7,908 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 276 | $7,774 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 42 | $6,100 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $5,548 |
| Levocetirizine Dihydrochloride | 485 | $5,493 |
| Fluticasone Propionate HfaFluticasone Propionate | 22 | $5,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $749 | $212,949313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $195 | $17,20229 claims |
| MerckDulera | $14 | $10,70229 claims |
| Boehringer IngelheimSpiriva Respimat | $15 | $9,88417 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $41 | $5,54820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in Lexington
- Elizabeth SaltLexington$89K
- Alisha ClemonsLexington$55K
- Timothy SmallwoodLexington$27K
- Lauren MaupinLexington$18K
- Angela CrutcherLexington$16K
- Emily MesserliLexington$13K
- Rhiannon BlackLexington$12K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.